Oncology · ImmunomodulatorRegulatory Approvalregulatorymid-term

Teva Pharmaceuticals submits supplemental application for Pomalidomide

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Teva25 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 12:31:23 AM

Assessment confidence: 58% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Teva Pharmaceuticals' submission of a supplemental application for Pomalidomide is a significant regulatory event that could reshape competitive dynamics in the oncology market. Portfolio teams must evaluate the implications for market positioning and pricing strategies as the FDA reviews this application. Regulatory context from FDA (FDA AP — POMALIDOMIDE (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential impact of this submission on market dynamics and pricing strategies. The strongest clinical anchor is Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With PD-L1 Expression < 1% or (ClinicalTrials.gov), sponsor/company relevance (novartis). In Oncology · Immunomodulator, 6 regulatory and 3 competitive items passed relevance filtering for Teva.

Competitive Pressure

The most relevant competitive pressure comes from Lupin's Lenalidomide ANDA214398 Receives Abbreviated Approval (Humanexa Signals) — moderate corpus alignment. Secondary pressure from FDA Grants Approval for Thalidomide ANDA213267 by NATCO. This submission could enhance Teva's position in the oncology market, particularly for therapies involving Pomalidomide.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — POMALIDOMIDE (SUPPL) (FDA). Entity match (teva); Regulatory pathway relevance (nda). The outcome of the FDA's review of this supplemental application will determine the regulatory landscape for Pomalidomide, impacting compliance and market entry timelines.

Key Risks

Elevated medium regulatory exposure for Teva could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, Teva could gain a stronger foothold in the oncology market, potentially affecting pricing and market share for existing therapies involving Pomalidomide.
Lead sponsor: Jazz Pharmaceuticals. Collaborators: Jazz Pharmaceuticals Ireland Limited.
Upside for Teva may improve if Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the potential impact of this submission on market dynamics and pricing strategies.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's response to the supplemental application and any subsequent market entry timelines.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — POMALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (teva); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — POMALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (pomalidomide); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — POMALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (pomalidomide); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — POMALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (pomalidomide); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — POMALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (pomalidomide); Regulatory pathway relevance (nda)
FDA document
View source
IND Application Reporting: IND Safety Reports
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With PD-L1 Expression < 1% or
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of Foot Massage on Pain and Analgesic Consumption in Total Knee Prosthesis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Influence of Parent-mediated mHealth Motor Skill Intervention on Preschool Children's Motor Skills and Cognitive Function
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Lupin's Lenalidomide ANDA214398 Receives Abbreviated Approval
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Thalidomide ANDA213267 by NATCO
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Supplemental Application for SARCLISA (Isatuximab-IRFC)
Humanexa Signalsmedium relevance
Moderate corpus alignment

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The application of growth factors in bone tissue engineering delivery systems and collaborative innovation strategies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The regulatory roles of non-coding RNAs in aerobic glycolysis and therapeutic potential in pancreatic ductal adenocarcinoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Teva
Pomalidomide

Commercial impact

medium

If approved, Teva could gain a stronger foothold in the oncology market, potentially affecting pricing and market share for existing therapies involving Pomalidomide.

Regulatory impact

medium

The outcome of the FDA's review of this supplemental application will determine the regulatory landscape for Pomalidomide, impacting compliance and market entry timelines.

What to watch

Monitor the FDA's response to the supplemental application and any subsequent market entry timelines.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.